Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Elderly mRCC (SERCC)
NCT01342627Phase 2Terminated
- Sponsor
- Centro di Riferimento Oncologico di Aviano
- Start
- Oct 2010
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in metastatic renal cell carcinoma (mRCC), sponsored by Centro di Riferimento Oncologico di Aviano. Primary endpoint: Efficacy of patient education program in the reduction of Hand-Foot Skin Reaction (HFSR) at 1 year. Started Oct 2010; status: terminated.
02
Drugs
sorafenib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT01342627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01342627.